Clinical Trial Update: Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating psilocybin for co-occurring major depressive disorder and borderline personality disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Personality Disorder
• Major Depressive Disorder

Drugs mentioned

• Psilocybin (psilocybin)

Snippet

Sponsor: University of Chicago | Conditions: Borderline Personality Disorder, Major Depressive Disorder | Phase 2 | Status: COMPLETED